(CIDRAP News) – The era of cell-based influenza vaccine production in the United States seemed to move closer today as Novartis unveiled its new, nearly billion-dollar manufacturing plant in Holly Springs, N.C., but onshore production and marketing of cell-based vaccines remains a few years away.
(CIDRAP News) Against the backdrop of a global struggle to solve a dispute related to H5N1 avian influenza virus sharing and an anxious watch over the novel H1N1 virus sweeping the globe, a new public database for sharing influenza genetic sequences is easing the flow of data and winning the support of a growing community of researchers and health officials, even some from countries that have sparred in the past over intellectual property rights.
The World Health Organization (WHO) reported 331 cases of swine influenza H1N1 in 11 countries as of 6 a.m. GMT today. The case numbers by country are United States, 109 (1 death) (these are yesterday's totals); Mexico, 156 (9 deaths), Canada, 34; Spain, 13; United Kingdom, 8; New Zealand, 3; Germany, 3; Israel, 2; and 1 each in Austria, the Netherlands, and Switzerland. [WHO update 7]
(CIDRAP News) This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.